Weight Loss

Editorial disclosure: TotalCareMedical.com is an independent health and wellness research publication. This comparison article is for educational and informational purposes only. Pricing, program details, and availability for all platforms cited are subject to change; verify current details directly with each provider. This article does not constitute medical advice. Compounded medications require evaluation by a licensed healthcare provider.

How to Read a GLP-1 Telehealth Comparison Honestly

The GLP-1 telehealth market has more than a dozen active platforms and a comparison landscape dominated by affiliate-driven content that ranks providers based on commission rates rather than program quality. This comparison uses five criteria that actually matter for patients: verified all-in pricing (not just the introductory rate), coaching structure and documented quality, pharmacy transparency, medication access (compounded vs. brand-name options), and program flexibility (month-to-month vs. prepay commitment). RNK Health is evaluated against competitors on these criteria using publicly available information as of publication.

For the full RNK Health program assessment, see the complete editorial review. For context on what compounded GLP-1 medications are, see our educational guide. For side effect considerations relevant across all platforms, see the safety guide.

The Comparison Framework

Five criteria, equally weighted in the editorial assessment: (1) Verified all-in monthly pricing at the semaglutide and tirzepatide tier — not the first-month promotional rate, but the ongoing rate at a starting dose. (2) Coaching structure — included vs. add-on, documented format and frequency, or absent. (3) Pharmacy transparency — is the compounding pharmacy identified? Is 503A/503B status disclosed or verifiable? (4) Medication access — compounded only, or access to brand-name FDA-approved options with insurance navigation. (5) Program flexibility — month-to-month or prepay commitment; cancellation terms.

Criteria that are NOT in this comparison: star ratings from review aggregators (subject to manipulation and selection bias), before/after testimonials (not clinical evidence), and promotional pricing that requires coupon codes not prominently disclosed on the main product page.

RNK Health

Injectable semaglutide: $197/month. Oral semaglutide: $198/month. Tirzepatide: $297/month. All prices all-inclusive — medication, physician oversight, personal coaching, supplies, shipping. Month-to-month, no contract. 48-hour delivery. All 50 states. Pharmacy disclosed (Springville, UT). No brand-name medication access based on available information.

Editorial assessment: Strong all-in pricing transparency, coaching included as standard at a competitive price point, pharmacy address disclosed, flexible commitment model. The gap: no documented coaching credential standards, no brand-name medication pathway for patients whose insurance may cover Wegovy or Zepbound.

Eden Health

Eden Health offers compounded semaglutide and tirzepatide with flat-rate pricing (does not increase with dose changes, which is a meaningful differentiator as patients titrate up), included coaching, and a 24/7 health coach access feature. Trade-offs: requires a 3-month prepaid commitment; labs are not included in the monthly rate and must be obtained separately. Tirzepatide pricing around $249/month (first month) and ongoing rates around $349/month on month-to-month basis, based on publicly available information. Month-to-month flexibility is less than RNK Health's model. The 24/7 coach access is a genuine differentiator for patients who want immediate support rather than scheduled touchpoints.

Noom Med

Noom Med operates differently from most compounded GLP-1 platforms: its primary offering is brand-name tirzepatide (Zepbound) with insurance support and a same-day prescription model, plus a sophisticated behavior change app (Welli AI companion, one-on-one coaching, meal plans, fitness program). Trade-offs: billing is 12 weeks upfront — not month-to-month — and the cancellation process is more involved than most competitors. For patients who have insurance that may cover brand-name tirzepatide, Noom Med's insurance navigation is a meaningful advantage. For patients paying out-of-pocket for compounded medications, RNK Health's all-in pricing is lower and the commitment structure is more flexible.

Henry Meds

Henry Meds is the no-frills option: no coaching, no membership fee, cash-pay only (no insurance), extremely simple intake. Pricing varies by dose and format; with promotional coupon codes, compounded semaglutide can start below $150/month. The trade-off is complete absence of coaching or lifestyle support — it is medication access only. For a patient who has established habits, a clear protocol, and wants the lowest possible cost for medication access, Henry Meds is a rational choice. For a patient who wants guidance, accountability, and support through the adjustment and maintenance phases, the absence of coaching is a meaningful structural gap that Henry Meds does not fill.

Mochi Health

Mochi Health offers compounded semaglutide at a flat $99/month at any dose — the lowest verified pricing in the category for semaglutide at publication — with physician oversight and pharmacy fulfillment. Trade-offs: no coaching included at that price point, and the flat-rate model at a very low price point raises legitimate questions about the sustainability of physician oversight quality at scale. Not available in all states. For pure price minimization with physician oversight, Mochi Health is a competitive option. For a program that includes active coaching and lifestyle support, the $197/month RNK Health all-in price includes features that Mochi Health's base plan does not.

SynergyRx GLP-1

SynergyRx is one of the platforms our editorial team has reviewed independently on TotalCareMedical.com. It offers access to both compounded and FDA-approved brand-name GLP-1 medications when clinically appropriate, with telehealth consultation and home delivery. For patients who want the flexibility to access brand-name options alongside compounded medications based on physician evaluation, SynergyRx offers a broader medication access model than RNK Health. See our SynergyRx GLP-1 review for the full assessment.

TrimRx

TrimRx is a streamlined telehealth platform offering compounded semaglutide and tirzepatide with competitive pricing. Our editorial team reviewed TrimRx independently — see the TrimRx GLP-1 review for detailed assessment. For patients comparing TrimRx and RNK Health specifically, the coaching inclusion and pharmacy disclosure at RNK Health are meaningful structural differences.

How to Decide: A Framework for Patients

The right platform depends on which of these patient profiles fits best. If brand-name medications with insurance coverage are a priority: evaluate Noom Med, WeightWatchers Clinic, or PlushCare — platforms with established insurance navigation infrastructure. If coaching and behavioral support are a priority and budget allows: RNK Health (coaching included, month-to-month) or Eden Health (24/7 coach access, 3-month commitment) are the strongest options in the compounded category. If the lowest possible price for medication access is the priority, with established habits already in place: Henry Meds or Mochi Health serve that profile. If flexibility — month-to-month, no prepay, cancel anytime — is essential: RNK Health's commitment model is among the most flexible in the category.

The question that should precede platform selection: Have I spoken with my primary care provider about whether GLP-1 therapy is appropriate for my specific health situation? A telehealth platform intake process is a prescribing mechanism, not a comprehensive metabolic evaluation. These programs work best for patients who have had that broader conversation with a provider who knows their full health picture.

Frequently Asked Questions

How does RNK Health compare to Noom Med?

Noom Med offers brand-name tirzepatide with insurance navigation and a robust behavior app. Trade-offs include 12-week prepay billing. RNK Health offers compounded GLP-1s, month-to-month flexibility, coaching included, and lower all-in pricing — without brand-name medication access.

How does RNK Health compare to Eden Health?

Eden Health has flat-rate compounded pricing (no dose-tier increases), 24/7 coach access, and a 3-month prepay commitment. RNK Health is month-to-month with no prepay requirement — more flexible for patients uncertain about long-term commitment.

Does RNK Health offer brand-name GLP-1 medications?

Based on available information, RNK Health's programs center on compounded semaglutide and tirzepatide. Patients seeking brand-name medications with insurance support should evaluate Noom Med, WeightWatchers Clinic, or PlushCare.

Which GLP-1 platform is cheapest in 2026?

The lowest published compounded semaglutide rates start below $100/month (Mochi Health, with limitations). RNK Health's $197/month all-inclusive rate is competitive when coaching, supplies, and shipping are factored into the comparison rather than medication cost alone.

Editorial disclosure: TotalCareMedical.com is an independent health and wellness research publication. This article provides educational information about the known side effect profile and safety considerations for GLP-1 receptor agonist medications. It does not constitute medical advice. Consult your healthcare provider before starting any prescription medication program. Compounded medications from RNK Health have not been reviewed or approved by the FDA for safety, effectiveness, or quality.

Why a Dedicated Safety Article Matters Here

GLP-1 receptor agonist medications have one of the most-studied clinical profiles of any weight management medication class in recent history. That evidence base is an asset — it means the risk profile is not theoretical; it is documented, quantified, and categorized. A reader who understands this profile before starting makes better decisions about whether to start, how to manage the adjustment period, what symptoms warrant immediate provider contact, and what long-term considerations to build into their approach. This article organizes that information from the peer-reviewed literature and approved prescribing information for semaglutide and tirzepatide. It applies to RNK Health's compounded versions of these active ingredients with one caveat: the specific risk data comes from trials of brand-name, FDA-approved formulations. Compounded versions have the same active pharmaceutical ingredient but have not undergone independent efficacy and safety trials as finished products.

For the full RNK Health program review, see the complete editorial assessment. For the mechanism and trial data comparison, see the semaglutide vs. tirzepatide guide.

Common Side Effects: What to Expect

The most frequently reported side effects of both semaglutide and tirzepatide are gastrointestinal. In the STEP-1 trial of semaglutide 2.4 mg, nausea occurred in approximately 44% of participants in the semaglutide group, vomiting in approximately 24%, diarrhea in approximately 30%, and constipation in approximately 24%. In the SURMOUNT-1 trial of tirzepatide, gastrointestinal adverse events were similarly common, with nausea reported in up to 31% of participants at the 15 mg dose. The pattern is consistent: GI side effects are common, predominantly mild to moderate in severity, most pronounced during dose escalation, and typically improve as the body adjusts.

Nausea is the most reported symptom, particularly in the first weeks after starting or after a dose increase. It is generally manageable through eating smaller meals, avoiding high-fat foods, eating slowly, and not lying down immediately after eating. Anti-nausea strategies should be discussed with your physician before starting if you have a history of nausea sensitivity.

Vomiting is less frequent than nausea but more disruptive. Persistent vomiting that prevents fluid intake warrants prompt contact with your provider — not waiting for the next scheduled check-in.

Constipation and diarrhea often alternate, reflecting the altered gastric emptying rate that is central to how these medications work. Adequate hydration and fiber intake help manage these effects.

Fatigue during the initial weeks of treatment is reported by some patients and may relate to reduced caloric intake, the body adjusting to altered appetite signaling, or both. This typically resolves.

Injection site reactions — mild itching, burning, or redness — are possible with injectable formulations. Rotating sites each week (abdomen, thigh, and upper arm are the standard sites) reduces the risk of localized skin changes.

Serious Risks: The Black Box Warning

Both semaglutide and tirzepatide carry an FDA black box warning — the most serious warning category — regarding thyroid C-cell tumors. In animal studies (rodents), both medications caused dose-dependent and duration-dependent increases in thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). Whether this risk applies to humans is unknown — human thyroid C-cells have GLP-1 receptors, but at lower density than rodents. No human cases of MTC have been definitively attributed to GLP-1 receptor agonist use in clinical trial populations to date.

The clinical implication is that GLP-1 receptor agonists are contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2). This is a screening question during the RNK Health intake process. Patients must answer it accurately. Contact your provider immediately if you develop any lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath during treatment — these may be symptoms requiring thyroid evaluation.

Standard Contraindications

Beyond the thyroid history contraindication, standard clinical contraindications for GLP-1 receptor agonist therapy include: current or planned pregnancy (GLP-1 medications should be discontinued at least two months before a planned pregnancy, given potential fetal risk based on animal data); active breastfeeding; personal history of pancreatitis; severe gastrointestinal conditions such as gastroparesis; end-stage renal disease on or approaching dialysis; end-stage liver disease (cirrhosis); active eating disorder; and known hypersensitivity to the active pharmaceutical ingredient. This list is not exhaustive. A complete medical history review with your licensed physician is the appropriate mechanism for assessing individual contraindications — not a checklist article.

If any of these conditions applies to you, disclose it during the RNK Health intake process. A physician who sees a contraindication should not issue the prescription. If you believe you disclosed a contraindication and received a prescription anyway, contact RNK Health patient support at (347) 588-2100 and verify the situation before beginning treatment.

Pancreatitis: The Risk and the Recognition

Acute pancreatitis has been reported in patients taking GLP-1 receptor agonists in post-marketing surveillance, though a definitive causal relationship has not been established. Patients with a history of pancreatitis are typically counseled to avoid this medication class. Any severe abdominal pain that radiates to the back, is persistent, and is accompanied by nausea and vomiting during GLP-1 treatment should be evaluated promptly by a medical provider — do not assume it is routine GI side effects without ruling out pancreatitis.

Muscle Loss: The Underreported Risk

GLP-1 medications reduce total caloric intake by reducing appetite. When caloric intake is substantially reduced without adequate protein intake and resistance exercise, the body loses lean muscle mass alongside fat. This is not a drug-specific side effect — it is a physiology-level response to caloric deficit that applies to any weight loss intervention. But GLP-1 medications are effective enough at producing caloric deficit that the muscle loss risk is real and deserves proactive management rather than retrospective recognition.

Patients on GLP-1 therapy should discuss protein targets with their physician or coach — general guidance from obesity medicine professionals suggests a minimum of 1.2 grams of protein per kilogram of body weight per day during active weight loss, though individual targets vary. Resistance exercise three or more times per week helps preserve lean mass. This is one specific area where RNK Health's included coaching may provide real value — helping patients build and sustain the protein and exercise habits that protect their lean body composition during the weight loss phase.

What to Do When Side Effects Occur

Mild GI symptoms: tolerate, modify diet, maintain hydration, and notify your provider at the next scheduled contact. Persistent nausea or vomiting that prevents eating or drinking: contact your provider promptly — dose adjustment may be appropriate. Any of the following warrant immediate contact with RNK Health patient support at (347) 588-2100 or emergency care if severe: severe abdominal pain, significant vision changes, chest pain, signs of severe allergic reaction (facial swelling, difficulty breathing, rash), or any new lump or swelling in the neck.

Weight Regain After Stopping: Setting Accurate Expectations

Clinical evidence is unambiguous on this point: most patients who discontinue GLP-1 receptor agonist therapy regain a substantial portion of lost weight within months. A 1-year follow-up study of the STEP-1 trial (published in Diabetes, Obesity and Metabolism, 2022) found that participants who discontinued semaglutide regained two-thirds of the weight they had lost within 12 months of stopping. This is not a failure of the medication — it reflects the mechanism. GLP-1 medications manage a hormonal signaling pathway; when the medication stops, the signaling stops. Long-term weight management typically requires either continued medication, a sustained lifestyle foundation robust enough to maintain reduced intake independently, or both.

Before starting any GLP-1 program, including RNK Health's, patients should have this conversation explicitly with their physician: What is the plan for long-term maintenance? Is this a finite course with a defined exit strategy, or a long-term management tool? What lifestyle habits will be established during treatment to maximize durability of results? These are not hypothetical questions — they are planning questions that separate programs with long-term value from those that produce temporary outcomes.

Frequently Asked Questions

What are the most common side effects?

Nausea, vomiting, diarrhea, constipation, and abdominal discomfort — predominantly during dose escalation and typically improving over time.

Who should not use GLP-1 medications?

Standard contraindications include personal or family history of medullary thyroid carcinoma or MEN 2, current or planned pregnancy, breastfeeding, history of pancreatitis, severe GI conditions, and end-stage kidney or liver disease. Full evaluation by a licensed physician is required.

What is the thyroid risk?

Animal studies showed thyroid C-cell tumors with GLP-1 medications. The relevance to humans is unknown. As a precaution, these medications are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or MEN 2. Report any neck lumps, hoarseness, or swallowing difficulty to your provider immediately.

What should I do if I experience severe side effects?

Severe abdominal pain, persistent vomiting, signs of allergic reaction, chest pain, or vision changes require immediate provider contact — RNK Health patient support: (347) 588-2100 — or emergency care if severe.

Does stopping GLP-1 medication lead to weight regain?

Yes. Clinical evidence shows most patients regain significant weight after discontinuing GLP-1 therapy. Long-term maintenance planning — medication continuity, lifestyle foundation, or both — should be part of the starting conversation with your provider.

What monitoring should occur during treatment?

Baseline kidney and liver function, thyroid history screening, ongoing GI symptom monitoring especially during dose escalation, and blood glucose monitoring for diabetic or prediabetic patients. Discuss your monitoring plan with your RNK Health physician at the outset.

Is muscle loss a risk?

Yes. Caloric deficit from GLP-1 therapy can cause muscle loss alongside fat loss. Adequate protein intake and regular resistance exercise throughout treatment are the primary countermeasures. RNK Health's included coaching may help patients build these habits.

What are the injection site considerations?

Weekly subcutaneous injections in the abdomen, thigh, or upper arm. Rotate sites weekly. Mild itching, burning, or redness at the site is possible. RNK Health includes required supplies with each plan.

Editorial disclosure: TotalCareMedical.com is an independent health and wellness research publication. This article is for educational and informational purposes only and does not constitute medical advice. All medication decisions should be made in consultation with your licensed healthcare provider. Compounded medications have not been reviewed or approved by the FDA for safety, effectiveness, or quality.

The Core Question

If you are considering RNK Health and have reached the point of choosing between compounded semaglutide and compounded tirzepatide, you are asking the right question. These are not equivalent medications — they work through different mechanisms, have different clinical trial profiles, and carry different price points within RNK Health's program structure. This article gives you the verified information needed to have a productive conversation with the physician who reviews your case. It does not make the choice for you. That is your physician's job.

For a full assessment of how RNK Health's program works, including coaching structure and pharmacy details, see the complete RNK Health review. For foundational context on what compounded GLP-1 medications are, see our plain-language GLP-1 explainer.

The Mechanism Difference: One Receptor vs. Two

Semaglutide is a GLP-1 receptor agonist. It binds to GLP-1 receptors — found in the pancreas, stomach, brain, liver, and other tissues — and activates the same signaling pathways that the body's naturally produced GLP-1 hormone activates. The effects include increased insulin secretion in response to glucose, reduced glucagon release, slowed gastric emptying, and reduced appetite through central nervous system signaling at the hypothalamus and brainstem.

Tirzepatide adds a second mechanism. It is a dual GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist. GIP is another incretin hormone produced in the gut in response to food, with roles in insulin secretion, fat metabolism, and — when its receptor is activated pharmacologically in combination with GLP-1 — potentially enhanced effects on appetite regulation and energy balance. In simple terms: semaglutide works through one hormonal lock; tirzepatide works through two simultaneously.

The clinical significance of that second mechanism is not just theoretical — it showed up clearly in phase 3 trial data. But trial comparisons require careful interpretation, which the next section addresses.

What the Phase 3 Trials Show (and What They Don't)

The STEP-1 trial (Wilding et al., New England Journal of Medicine, 2021) was a randomized, double-blind, placebo-controlled trial of 68 weeks in 1,961 adults with obesity or overweight with at least one comorbidity, without type 2 diabetes. Participants received semaglutide 2.4 mg weekly plus lifestyle intervention or placebo plus lifestyle intervention. The semaglutide group lost an average of 14.9% of body weight from baseline; the placebo group lost 2.4%. This is peer-reviewed efficacy data for FDA-approved Wegovy at its approved dose.

The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) was a randomized, double-blind, placebo-controlled trial of 72 weeks in 2,539 adults with obesity or overweight with at least one comorbidity, without type 2 diabetes. Participants received tirzepatide at 5 mg, 10 mg, or 15 mg weekly, or placebo — all combined with lifestyle intervention. Average weight loss was 15.0%, 19.5%, and 20.9% at the respective tirzepatide doses, versus 3.1% in the placebo group. This is peer-reviewed efficacy data for the active ingredient in FDA-approved Zepbound.

The critical interpretive point: these are two separate trials with similar but not identical patient populations, different trial durations, and different doses. They are not a head-to-head comparison. In the only direct head-to-head trial between the two molecules in type 2 diabetes patients (SURPASS-2, published in New England Journal of Medicine 2021), tirzepatide at all doses produced greater weight reduction than semaglutide 1 mg — but the weight loss indication uses a different (higher) semaglutide dose than was studied head-to-head. The takeaway is directional: tirzepatide's dual mechanism appears to produce greater average weight loss in clinical trials. The exact magnitude of that difference in a given patient is unknowable in advance.

Both sets of trials used brand-name, FDA-approved formulations — not compounded versions. No peer-reviewed trials have independently validated equivalent outcomes for compounded semaglutide or tirzepatide specifically. This is a scope caveat that applies to every compounded GLP-1 program, not just RNK Health's.

Pricing Within RNK Health's Program

At RNK Health, as of publication:

Injectable semaglutide: $197/month all-inclusive (medication, physician oversight, coaching, supplies, shipping). Oral semaglutide: $198/month all-inclusive. Injectable tirzepatide: $297/month all-inclusive.

The tirzepatide premium within RNK Health's program is $100/month over injectable semaglutide — $1,200/year. That is not a trivial sum, and it is a legitimate factor to weigh against the clinical profile difference. Whether that premium is appropriate for a given patient depends on their health history, starting BMI, comorbidities, prior treatment history, and physician recommendation. A provider who recommends tirzepatide for a patient with significant insulin resistance and type 2 diabetes is operating differently than one who recommends it as a first-line option for a patient with modest weight to lose. These are clinical judgments, not consumer choices.

The Oral Semaglutide Question

RNK Health's oral semaglutide option ($198/month) deserves separate examination. The FDA-approved oral semaglutide tablet (Rybelsus, approved for type 2 diabetes, not for weight management) uses a proprietary absorption enhancer — SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) — that enables meaningful bioavailability of semaglutide when taken orally, under specific conditions (fasting, small amount of water, 30 minutes before food). Most compounded oral semaglutide formats — including dissolving tablets and lozenges — do not incorporate this technology.

What this means practically: the bioavailability of compounded oral semaglutide is not established by peer-reviewed pharmacokinetic studies. It may be lower than injectable compounded semaglutide. Patients who prefer to avoid injections should ask their physician specifically about the evidence base for the oral compounded format relative to the injectable option before choosing it on the basis of needle aversion alone. There may be an appropriate patient for oral compounded semaglutide — but that patient should make the choice with accurate information about the bioavailability question.

Questions to Bring to Your Physician Review

The RNK Health intake process ends with a licensed physician determining your eligibility and the appropriate medication. Making that conversation productive requires you to show up with the right questions. Based on the clinical landscape and the distinguishing features of these two options, the most useful question is: Do my comorbidities (if any) favor one mechanism over the other? Is my starting BMI or weight loss target one where the tirzepatide data's higher average weight loss is clinically meaningful for my situation, or is the semaglutide data's profile sufficient? Are there any elements of my medical history that make one option preferable or one a relative contraindication? Given my goals and history, does the $100/month cost difference favor starting with semaglutide and escalating only if response is insufficient?

These questions turn a prescribing encounter into a clinical conversation. They are also the questions that will tell you whether the physician reviewing your case is genuinely engaging with your history or running through a standardized algorithm. Both are informative.

Side Effects: Are They Different Between the Two?

Both semaglutide and tirzepatide share a common side effect profile dominated by gastrointestinal symptoms: nausea, vomiting, diarrhea, constipation, and abdominal discomfort, particularly during dose escalation. These effects typically improve over time as the body adjusts. Injection site reactions are possible with injectable formulations of both medications.

The side-effect profiles are similar because both medications activate GLP-1 receptors—the mechanism responsible for most GI effects. Tirzepatide's additional GIP receptor activation does not appear to substantially alter the side-effect profile, though individual tolerability can vary. For a complete, dedicated guide to side effects, contraindications, and safety monitoring for RNK Health's programs, see our RNK Health safety and side effects guide.

Frequently Asked Questions

What is the difference between semaglutide and tirzepatide?

Semaglutide activates one receptor pathway (GLP-1); tirzepatide activates two (GLP-1 and GIP). Phase 3 trial data shows tirzepatide produced greater average weight loss at its highest studied dose, though these were separate trials — not a direct head-to-head comparison in weight management populations.

Is tirzepatide better than semaglutide for weight loss?

In separate phase 3 trials, tirzepatide at 15 mg weekly produced average weight loss of approximately 20.9% over 72 weeks (SURMOUNT-1), while semaglutide at 2.4 mg weekly produced approximately 14.9% over 68 weeks (STEP-1). These were separate trials, not direct head-to-head comparisons. Individual response and tolerability vary.

Which costs more at RNK Health — semaglutide or tirzepatide?

As of publication, injectable semaglutide is $197/month and tirzepatide is $297/month at RNK Health, both all-inclusive. The $100/month difference should be weighed against clinical factors in conversation with your physician.

Can I switch between semaglutide and tirzepatide at RNK Health?

Medication changes require physician guidance. Switching involves restarting titration at a low dose and is a clinical decision based on individual response and goals.

What is the oral semaglutide option at RNK Health?

RNK Health offers oral dissolving semaglutide at $198/month. Most compounded oral formulations lack the SNAC absorption enhancer used in FDA-approved Rybelsus. Patients should ask their physician about bioavailability expectations before choosing the oral format.

How long does it take to see results?

Appetite reduction typically begins within the first weeks. In clinical trials of brand-name formulations, measurable weight loss appeared within four weeks, with most weight loss occurring in the first four to five months. Individual results with compounded versions may differ.

Editorial disclosure: TotalCareMedical.com is an independent health and wellness research publication. This article is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Compounded medications offered through RNK Health require evaluation by a licensed healthcare provider and have not been reviewed or approved by the FDA for safety, effectiveness, or quality. Consult your healthcare provider before beginning any weight management program.

The Short Answer

RNK Health is a telehealth-based weight management and longevity platform. Patients complete an online health assessment, a licensed physician reviews the information and determines whether a prescription is appropriate, and if so, compounded medication is shipped directly to the patient's home. The primary programs involve compounded semaglutide and compounded tirzepatide — two GLP-1 receptor agonist active ingredients with an established body of clinical literature. RNK Health also offers NAD+ and Sermorelin programs for patients interested in broader longevity support.

This article explains what GLP-1 therapy is, how compounded medications differ from brand-name options, how the RNK Health process works, and what prospective patients should understand before starting. For verified pricing and a full program assessment, see our complete RNK Health review.

What Is GLP-1 Therapy?

GLP-1 stands for glucagon-like peptide-1 — a hormone naturally produced in the gut in response to food intake. It plays several roles in metabolic regulation: it stimulates the pancreas to release insulin in response to rising blood glucose, slows gastric emptying (the rate at which food leaves the stomach), and acts on areas of the brain involved in appetite signaling, producing a sense of fullness earlier and for longer than food alone typically achieves.

GLP-1 receptor agonists are medications designed to bind to the same receptors that the body's natural GLP-1 hormone activates, amplifying these effects. They do not stimulate the central nervous system the way older appetite suppressants did. They work through a hormonal pathway, which is why the clinical profile — including the side effect profile — is different from previous generations of weight management medications.

The two active pharmaceutical ingredients RNK Health's programs are built around — semaglutide and tirzepatide — are the same ingredients in the brand-name FDA-approved medications Wegovy (semaglutide, approved for chronic weight management), Ozempic (semaglutide, approved for type 2 diabetes), Zepbound (tirzepatide, approved for chronic weight management), and Mounjaro (tirzepatide, approved for type 2 diabetes). The distinction between the brand-name and compounded versions matters and is explained below.

What Does “Compounded” Mean?

Pharmaceutical compounding is the practice of a licensed pharmacist preparing a customized medication for an individual patient based on a licensed prescriber's order. Compounding has a recognized place in medicine — it allows access to medications in formulations or doses that are not commercially available, for patients with allergies to inactive ingredients in commercial products, or when commercial products are unavailable.

Compounded semaglutide and tirzepatide contain the same active pharmaceutical ingredients as the brand-name versions. What they do not have is FDA approval as finished drug products. This means they have not undergone the FDA's review process for safety, effectiveness, or manufacturing quality as a finished formulation. They are prepared by state-licensed compounding pharmacies under requirements established by state pharmacy boards and, for outsourcing facilities (503B pharmacies), by FDA oversight as well.

This distinction is not a reason to categorically avoid compounded GLP-1 medications — it is a reason to understand exactly what you are taking and to ensure the compounding pharmacy involved operates to high standards. The questions to ask a compounding pharmacy before starting are: What is your 503A or 503B designation? Are you on the FDA's registered outsourcing facilities list? Do you test finished product for potency and sterility? An operation with transparent answers to all three is meaningfully different from one that is evasive.

RNK Health's compounding pharmacy is located at 863 W 450 S, Suite 101, Springville, UT 84663. Patients can use this address to look up the pharmacy's registration status with the Utah Division of Professional Licensing and the FDA's outsourcing facility database.

How Does the RNK Health Process Work?

The intake process is fully online. Patients complete a digital health questionnaire covering their medical history, current medications, weight history, and treatment goals. A licensed physician reviews this information and determines whether a prescription for compounded semaglutide or tirzepatide is clinically appropriate. Patients who do not meet prescribing criteria are not approved — which is how a medically responsible program operates.

If a prescription is issued, RNK Health states that medication is compounded and shipped within 48 hours to the patient's address via private home delivery. All plans include the medication itself, the physician consultation and prescription management, personal coaching, required self-administration supplies (syringes and alcohol swabs for injectable formulations), and shipping — with no separately billed fees. Plans are month-to-month with no long-term contract.

Patients seeking the most detailed comparison of semaglutide and tirzepatide within the RNK Health context — including mechanism differences, trial data, and how to think about which option to discuss with a provider — should read our semaglutide vs. tirzepatide guide for RNK Health patients.

Who Qualifies?

GLP-1 receptor agonist therapy for weight management is generally evaluated for adults who meet specific BMI criteria. Standard prescribing thresholds — consistent with the FDA-approved indications for Wegovy and Zepbound — include adults with a BMI of 30 or greater (classified as obesity), or adults with a BMI of 27 or greater (classified as overweight) who have at least one weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea.

These thresholds are guidelines, not guarantees. The prescribing decision belongs entirely to the licensed physician who reviews your specific intake information. Certain medical histories are standard contraindications that a reviewing physician will evaluate: personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, pancreatitis, severe gastrointestinal conditions, current or planned pregnancy, and end-stage kidney or liver disease, among others.

Full disclosure of your medical history during the intake process is not optional — it is the mechanism by which the platform ensures the medication is appropriate for you. Incomplete disclosure creates risk. Complete disclosure allows the physician to make an informed determination, and in some cases, to recommend a different treatment approach.

What Is NAD+ and How Does It Fit?

RNK Health's NAD+ offering sits in a different category from its GLP-1 programs. NAD+ (nicotinamide adenine dinucleotide) is a coenzyme involved in cellular energy metabolism, DNA repair, and mitochondrial function. Research on NAD+ supplementation in humans is an active and developing area; while preclinical and early-phase human studies show interesting signals around aging and metabolic function, large-scale randomized controlled trials establishing definitive clinical outcomes are still limited. Patients interested in NAD+ should review the current evidence with their healthcare provider and approach the category as an emerging area of inquiry rather than an established therapeutic intervention.

RNK Health offers NAD+ starting at $129/month in injectable, nasal spray, and liposomal liquid formats, giving patients format flexibility based on preference and comfort with self-administration.

The Bottom Line on What RNK Health Is

RNK Health is a telehealth platform that provides physician-supervised access to compounded GLP-1 medications — the same active ingredients as brand-name Wegovy and Zepbound — at a fraction of the brand-name price, with personal coaching included at no additional cost and a disclosed U.S.-based pharmacy. It is not a supplement program, not an over-the-counter solution, and not a substitute for a primary care relationship. It is a prescription telehealth service that operates within a recognized medical framework, with the attendant requirements that implies: a licensed prescriber, a licensed pharmacy, and patient responsibility for accurate medical disclosure.

For a complete program assessment including verified pricing, coaching details, and our editorial conclusions, see the RNK Health review. For safety considerations, contraindications, and what to watch for during treatment, see our RNK Health side effects and safety guide.

Frequently Asked Questions

What is RNK Health?

RNK Health is a telehealth platform that connects patients with licensed physicians who evaluate eligibility for compounded GLP-1 weight management medications — primarily compounded semaglutide and compounded tirzepatide — along with longevity therapies including NAD+. Available in all 50 states.

What does compounded mean for GLP-1 medications?

Compounded GLP-1 medications contain the same active pharmaceutical ingredient as brand-name versions but are prepared by a licensed compounding pharmacy. They are not FDA-approved as finished drug products and require a prescription from a licensed healthcare provider.

How does the RNK Health intake process work?

Patients complete a digital health assessment. A licensed physician reviews it and determines whether a prescription is appropriate. If approved, medication ships to the patient's address within approximately 48 hours of physician approval.

Who qualifies for GLP-1 therapy at RNK Health?

Standard GLP-1 prescribing criteria include adults with a BMI of 30 or greater, or adults with a BMI of 27 or greater with at least one weight-related comorbidity. Final eligibility is determined by the reviewing licensed physician.

Editorial disclosure: TotalCareMedical.com is an independent health and wellness research publication. This article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. RNK Health's programs involve compounded prescription medications that require evaluation by a licensed healthcare provider. Compounded medications have not been reviewed or approved by the FDA for safety, effectiveness, or quality. Consult your healthcare provider before beginning any weight management program.

What Is RNK Health?

RNK Health (myrnk.com) is a telehealth-based weight management and longevity platform that connects patients with licensed physicians who evaluate eligibility for compounded GLP-1 medications — primarily compounded semaglutide and compounded tirzepatide — along with wellness therapies including NAD+ and Sermorelin. The model mirrors the growing category of online-first GLP-1 clinics: patients complete a digital health assessment, a licensed physician reviews the information and determines eligibility, and if a prescription is appropriate, medication is compounded at a licensed U.S. pharmacy and shipped directly to the patient's door.

What distinguishes RNK Health from many competitors in this space is the inclusion of a dedicated personal coach at no additional cost with every plan. In a market where coaching is often a premium add-on—or absent entirely—this bundled structure is worth honest examination, which this review does. We cover the program structure, verified pricing, medication options, pharmacy transparency, and the key questions any informed patient should ask before starting.

For a broader overview of what compounded GLP-1 medications are and how they differ from FDA-approved brand-name options, see our educational primer on RNK Health and compounded GLP-1 therapy.

What Medications Does RNK Health Offer?

RNK Health's primary treatment offerings involve the two most-studied GLP-1 active pharmaceutical ingredients in the weight management category: semaglutide and tirzepatide. Both are available only through a licensed provider evaluation, not over the counter.

Compounded semaglutide (injectable): Semaglutide is a GLP-1 receptor agonist — meaning it binds to the same receptor as the body's naturally occurring glucagon-like peptide-1 hormone, which plays a role in appetite signaling, gastric emptying rate, and insulin regulation. The FDA-approved injectable forms of semaglutide for chronic weight management are Wegovy (2.4 mg weekly) and Ozempic (approved for type 2 diabetes, sometimes prescribed off-label for weight management at a clinician's discretion). RNK Health's compounded semaglutide contains the same active pharmaceutical ingredient but is prepared by a compounding pharmacy rather than a pharmaceutical manufacturer — an important distinction covered in detail below.

Compounded semaglutide (oral dissolving): RNK Health also offers an oral semaglutide format. Oral administration of semaglutide raises pharmacokinetic considerations worth understanding. The FDA-approved oral semaglutide tablet (Rybelsus) uses a specialized absorption enhancer (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate, or SNAC) to achieve meaningful bioavailability. Most compounded oral semaglutide formulations — including oral dissolving tablets and lozenges — do not use this technology, and independent pharmacokinetic data on their absorption characteristics is limited. Patients considering oral compounded semaglutide should discuss expected bioavailability with their provider.

Compounded tirzepatide (injectable): Tirzepatide is a dual GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist. Where semaglutide targets one receptor, tirzepatide targets two. In the SURMOUNT-1 randomized controlled trial — a peer-reviewed study published in the New England Journal of Medicine — participants without diabetes taking tirzepatide at 15 mg weekly lost an average of 20.9% of body weight over 72 weeks, compared with 3.1% in the placebo group. FDA-approved tirzepatide for weight management is marketed as Zepbound (15 mg maximum weekly dose) and for diabetes as Mounjaro. RNK Health's compounded tirzepatide contains the same active ingredient in compounded form.

NAD+ and Sermorelin: RNK Health also offers NAD+ (nicotinamide adenine dinucleotide) supplementation starting at $129/month in injectable, nasal spray, and liposomal formats, as well as Sermorelin, a growth hormone releasing hormone analog. These fall outside the GLP-1 category and are not the primary focus of this review. Patients interested in these programs should discuss the evidence base and their individual suitability with a licensed provider.

Verified Pricing (as of Publication)

Pricing transparency is a legitimate differentiator in the GLP-1 telehealth space, where hidden fees and membership tiers are common. Based on publicly available information reviewed by our editorial team, RNK Health's published pricing structure is as follows:

Injectable semaglutide: $197/month, all-inclusive. Oral semaglutide: $198/month, all-inclusive. Injectable tirzepatide: $297/month, all-inclusive. All plans include medication, licensed physician consultation and prescription management, personal coaching, required supplies (syringes, alcohol swabs), and shipping. RNK Health states there are no hidden fees and the model is month-to-month with no long-term contract or cancellation penalty.

For context: brand-name Wegovy has a list price above $1,300/month, and brand-name Zepbound starts near $1,086/month at list price. Compounded alternatives from established competitors typically run $197–$399/month for semaglutide and $249–$399/month for tirzepatide, often without coaching included. RNK Health's tirzepatide pricing at $297/month all-inclusive is competitive for a plan that includes active physician oversight and personal coaching. Always verify current pricing directly with RNK Health before enrollment, as telehealth pricing in this category changes frequently.

The Coaching Model: What It Includes and What to Ask

Bundled personal coaching is the element RNK Health emphasizes most prominently. For patients new to GLP-1 therapy, this matters: GLP-1 medications reduce appetite, but long-term outcomes depend substantially on what patients do with that reduced appetite in terms of protein intake, resistance exercise, and behavioral anchoring. A personal coach who communicates with the prescribing physician and monitors progress can, in principle, help prevent common failure modes like muscle loss from inadequate protein intake during a caloric deficit.

What we cannot independently verify: the specific credentials or qualifications of RNK Health's coaches, the frequency and format of coaching touchpoints, or whether coaching interactions are primarily automated, asynchronous messaging, or synchronous calls. These are specific questions patients should ask during or before the intake process. A coaching program that consists of weekly check-in messages is substantively different from one that includes regular video or phone calls with a credentialed dietitian or health coach — and both can be marketed as “personal coaching.”

Pharmacy Transparency: What to Confirm Before Starting

RNK Health's compounding pharmacy is located at 863 W 450 S, Suite 101, Springville, UT 84663. The prescribing medical provider address is listed as 317 Sixth Avenue, Des Moines, Iowa 50309. This level of pharmacy address disclosure is better than many competitors in this space, who provide no pharmacy identification at all.

What patients should confirm directly: whether the pharmacy holds 503A or 503B designation with their state board, whether it appears on the FDA's list of registered outsourcing facilities, and whether it tests finished product for potency and sterility. These questions are reasonable, answerable, and the mark of a transparent compounding operation. A pharmacy that cannot answer them clearly is a pharmacy worth avoiding.

RNK Health states medications ship within 48 hours of physician approval via private home delivery. The program is available across all 50 states.

What the Clinical Evidence Shows About These Medications

It is important to distinguish between the evidence base for the active pharmaceutical ingredients (semaglutide and tirzepatide) and the evidence base for RNK Health as a specific program. The former is substantial. The latter involves no independent peer-reviewed outcomes data — which is true of virtually every telehealth GLP-1 platform, not a specific criticism of RNK Health.

For semaglutide: the STEP-1 randomized controlled trial (Wilding et al., New England Journal of Medicine, 2021) found that adults with obesity without diabetes who received semaglutide 2.4 mg weekly combined with lifestyle intervention lost an average of 14.9% of body weight over 68 weeks, compared with 2.4% in the placebo plus lifestyle group. For tirzepatide: the SURMOUNT-1 randomized controlled trial (Jastreboff et al., New England Journal of Medicine, 2022) found average weight loss of 15.0%, 19.5%, and 20.9% at tirzepatide doses of 5, 10, and 15 mg respectively over 72 weeks, compared with 3.1% in the placebo group. These trials used brand-name, FDA-approved formulations — not compounded versions. Individual results from compounded products may differ, and no compounded-specific outcome trials have been published as of this writing.

For broader context on how compounded semaglutide compares to tirzepatide specifically within RNK Health's program structure, see our semaglutide vs. tirzepatide decision guide for RNK Health patients.

Who RNK Health May Be Appropriate For

Based on standard GLP-1 prescribing criteria, candidates for GLP-1 receptor agonist therapy typically include adults with a BMI of 30 or greater, or adults with a BMI of 27 or greater who have at least one weight-related comorbidity (such as hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea). Prescribing decisions rest entirely with the licensed physician who reviews your intake form and health history — not with the platform itself, and not with this article.

RNK Health may not be appropriate for individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, current or planned pregnancy, a history of pancreatitis, end-stage kidney or liver disease, or certain other contraindications. Patients should disclose their complete medical history during the intake process. For a complete overview of risk factors and side effects, see our dedicated RNK Health side effects and safety guide.

Our Assessment

RNK Health is a structurally transparent GLP-1 telehealth program in a market that rewards opacity. All-inclusive pricing, a disclosed pharmacy address, 50-state availability, month-to-month flexibility, and bundled coaching at no additional cost are genuine differentiators — not marketing language that dissolves under scrutiny. The oral semaglutide bioavailability question and the coaching credential question are legitimate gaps that informed patients should close before enrolling. Neither is a disqualifying concern; both are questions with answerable answers.

What RNK Health is: a legitimate telehealth pathway to physician-supervised compounded GLP-1 therapy with competitive all-inclusive pricing and an above-average support model for this category. What it is not: a substitute for a comprehensive metabolic evaluation, ongoing lab monitoring, or a relationship with a primary care provider who knows your full health picture. These programs work best when they complement existing medical care — not when they replace it.

To see how RNK Health stacks up directly against other leading GLP-1 telehealth platforms on pricing, coaching, pharmacy transparency, and access to brand-name medications, see our full RNK Health vs. competitors comparison.

Frequently Asked Questions

What medications does RNK Health offer?

RNK Health offers compounded semaglutide in injectable and oral formats, compounded tirzepatide in injectable form, NAD+ therapy, and Sermorelin. All prescription medications require licensed physician evaluation before a prescription is issued.

How much does RNK Health cost?

As of publication, RNK Health's pricing starts at $197/month for injectable semaglutide, $198/month for oral semaglutide, and $297/month for tirzepatide. All plans include medication, physician oversight, personal coaching, supplies, and shipping. Verify current pricing directly with RNK Health.

Is RNK Health available in all states?

RNK Health states it operates in all 50 states. Patients should confirm availability in their specific state during the intake process.

Are RNK Health's medications FDA-approved?

No. RNK Health's GLP-1 medications are compounded. Compounded semaglutide and tirzepatide are not FDA-approved as finished drug products and have not undergone FDA review for safety, effectiveness, or quality. They contain FDA-approved active pharmaceutical ingredients but are prepared by a compounding pharmacy rather than a pharmaceutical manufacturer.

Does RNK Health include coaching?

Yes. RNK Health includes a dedicated personal coach with every plan at no additional cost. Patients should ask about coach credentials, touchpoint frequency, and the format of coaching interactions before enrolling.